As of Jun 28
| +0.001 / +0.16%|
The 2 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 2.63, with a high estimate of 3.50 and a low estimate of 1.75. The median estimate represents a +306.35% increase from the last price of 0.65.
The current consensus among 2 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.